Announced FDA approval for KIMMTRAK (tebentafusp-tebn) in January 2022, which is the first drug approved specifically for patients with metastatic uveal melanoma (mUM). It targets HLA-A *02:01-positive adult patients, representing approximately 45% of the uveal melanoma population. This drug competes with HEPZATO, which is approved to treat all mUM patients, including the remaining 55% of patients.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

Immunocore Holdings PLC

Develops and markets devices for local regional procedures such as trans-arterial chemoembolization (TACE, DEBTACE) and Radioembolization (SIRT, TARE, or Y90), which are alternatives to HEPZATO and CHEMOSAT. These procedures are not approved for the treatment of mUM.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

Boston Scientific Corp

Markets devices for local regional procedures like TACE and Radioembolization, which compete with HEPZATO and CHEMOSAT in the treatment of liver cancers. These procedures are not approved for mUM.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

Medtronic PLC

Offers devices for local regional procedures such as TACE and Radioembolization, which are alternatives to HEPZATO and CHEMOSAT for liver cancer treatments. These procedures are not approved for mUM.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

Merit Medical Systems Inc

Provides devices for local regional procedures like TACE and Radioembolization, which compete with HEPZATO and CHEMOSAT in the treatment of liver cancers. These procedures are not approved for mUM.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

AngioDynamics Inc

Developing darovasertib, an oral protein kinase C (PKC) inhibitor, in combination with crizotinib, a cMET inhibitor, targeting first-line HLA-A2 negative mUM patients. This combination has received FDA Fast Track designation and is being evaluated in a potentially registration-enabling Phase 2/3 trial. Additionally, a Phase 3 study for darovasertib as a neoadjuvant therapy in primary uveal melanoma is planned for the first half of 2025.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

IDEAYA Biosciences Inc

Investigating RP2, an oncolytic immunotherapy, for mUM. A randomized Phase 2/3 trial has been initiated to compare RP2 combined with nivolumab versus the combination of ipilimumab and nivolumab in immune checkpoint inhibitor-naïve adult patients with mUM. This product has not yet been approved for the treatment of mUM.  **[872912_0001628280-25-010797_dcth-20241231.htm:33]** 

Organization	Role	Date Range	Details
Vericel Corporation	Chief Financial Officer	June 2014 - October 2020	Key management member integrating a transformative acquisition and revising the business model
Biodel, Inc.	Chief Financial Officer and Vice President, Corporate Development	November 2007 - May 2014
NPS Pharmaceuticals Inc.	Chief Financial Officer and Vice President, Corporate Development	August 2002 - November 2007
Booz Allen	Principal	N/A	No specific dates provided
Lederle Labs and Wyeth Labs	Various Commercial Roles	N/A	No specific details available

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$564,240	Annual 2024	4.0% increase from 2023 base salary
Option Awards	$1,230,036	Vesting monthly over 3 years starting from Feb 12, 2024	301,500 shares granted at an exercise price of $4.78; vesting based on continued service

Metric	Details
Target Bonus Percentage	65.0% of base salary
Actual Payout	$366,756
Performance Achievement	100% based on corporate performance goals
Evaluation Areas	Clinical Trials, Regulatory, Commercial, Manufacturing, Finance
Payment Schedule	Annual 2024
Conditions	Awarded based solely on achievement of company performance goals; no additional vesting requirements

Gerard Michel

Also at DELCATH SYSTEMS

About

$DCTH Performance Under Gerard Michel

Past Roles

Fixed Compensation

Performance Compensation

Non-Equity Incentive Plan Compensation